FINDING YOUR MOMENT

Moments of Clarity shares personal stories from people living 
with nonsegmental vitiligo and mild to moderate atopic dermatitis, the most 
common form of eczema. Each story captures a turning point in their journey—from 
recognizing the need for support, to seeking care, to experiencing meaningful 
improvement* in their condition with the help of OPZELURA® (ruxolitinib) cream 1.5%.

Moments of Clarity shares personal stories from people living with nonsegmental vitiligo and mild to moderate atopic dermatitis, the most common form of eczema. Each story captures a turning point in their journey—from recognizing the need for support, to seeking care, to experiencing meaningful improvement* in their condition with the help of OPZELURA® (ruxolitinib) cream 1.5%.

Ray standing and smiling in front of a winner’s podium on a running track setting, sharing about his vitiligo repigmentation with Opzelura.
Ray standing and smiling in front of a winner’s podium on a running track setting, sharing about his vitiligo repigmentation with Opzelura.
Nonsegmental Vitiligo

Restoring lost pigment: Discover real stories from people living with nonsegmental vitiligo experiencing repigmentation.

*In a clinical study, 30% of patients achieved 75% improvement to vitiligo areas on the face at 6 months versus 13% using a non-medicated cream. Similar results were seen in another study.

Piper dancing and Adam sitting on a stool in a dance studio setting, discussing Piper's management of mild to moderate eczema with Opzelura.
Piper dancing and Adam sitting on a stool in a dance studio setting, discussing Piper's management of mild to moderate eczema with Opzelura.
Mild to Moderate Eczema

Calming the flare-ups: Discover real stories from people living with mild to moderate eczema and how they found relief.

*In a clinical study of patients 2-11, 57% of patients achieved clear or almost clear skin at 8 weeks versus 11% using a non-medicated cream. In a clinical study of patients 12+, 54% achieved clear or almost clear skin with OPZELURA at 8 weeks compared to 15% using a non-medicated cream. Similar results were seen in another clinical study.

Individuals were compensated for their participation.

Understanding Nonsegmental Vitiligo

Vitiligo is a chronic autoimmune condition where the body’s immune system mistakenly attacks the cells that give the skin color, causing white patches to appear on the skin. The most common type of vitiligo is nonsegmental vitiligo, where these patches appear on both sides of the body. Vitiligo affects an estimated 1.9 to 2.8 million people in the United States and can have a significant impact on their lives.

Sam standing in front of lockers, discussing her journey managing vitiligo with Opzelura.
Sam standing in front of lockers, discussing her journey managing vitiligo with Opzelura.

Real Stories From real people

Watch the video

Sarah

As a mom and educator living with vitiligo, Sarah wrestled with balancing her feelings about her vitiligo with being the role model she wanted to be for her daughter. Hear how Sarah found equilibrium with treatment and taking control back from her vitiligo. Results may vary.

Individuals were compensated for their participation.

Watch the video

Ray

After his later-in-life diagnosis, Ray applied the principles he cultivated as a professional runner to his journey navigating nonsegmental vitiligo. Learn how he stayed consistent with his vitiligo treatment and tracked his repigmentation to achieve his goals. Results may vary.

Individuals were compensated for their participation.

Watch the video

Sam

Sam used to spend hours in the morning using makeup to cover her loss of pigment from nonsegmental vitiligo. Listen to her new approach to time management and morning routine after repigmentation. Results may vary.

Individuals were compensated for their participation.

Watch the video

Rissa

When people made assumptions about the white patches on Rissa’s skin, she realized they saw her as someone with vitiligo rather than a person. She didn’t let this define her. Learn about her love of community, journey to finding a vitiligo treatment, and her hope for all people living with vitiligo. Results may vary.

Individuals were compensated for their participation.

A real patient smiling outside in a field, sharing their story managing vitiligo with Opzelura.

DISCOVER MORE MOMENTS

Every journey with vitiligo is unique. Hear from real people living with nonsegmental vitiligo on how they found their Moment of Clarity to take back control of their condition with OPZELURA.

See their stories
A real patient smiling outside in a field, sharing their story managing vitiligo with Opzelura.
A real patient smiling in their car, sharing their story of managing their vitiligo with Opzelura.
A real patient and caregiver smiling, arm in arm, sharing their story of managing vitiligo with Opzelura.
A real patient smiling in their car, sharing their story of managing their vitiligo with Opzelura.
A real patient and caregiver smiling, arm in arm, sharing their story of managing vitiligo with Opzelura.

Talk to a Doctor About Vitiligo Management

If you are experiencing challenges getting an in-person appointment with a physician who understands vitiligo, consider starting the conversation through telehealth. Connect with a provider who has the latest information on vitiligo and management options from the comfort of your own home.

Connect through telehealth

Incyte does not in any way control or influence any telemedicine healthcare provider. These healthcare providers exercise their own independent medical judgment and are under no obligation to prescribe any medication.

Person holding a tablet during a telehealth appointment.
Person holding a tablet during a telehealth appointment.

Mild to Moderate Eczema & OPZELURA

Atopic dermatitis (AD), the most common type of eczema, affects an estimated 2-3 million children aged 2-11 and more than 7.5 million people aged 12 and older in the United States. This chronic immune-mediated condition can lead to a cycle of itching and scratching, and each person’s experience with eczema is unique.

OPZELURA is a twice-daily cream for the treatment of mild to moderate eczema that has proven to provide clear or almost clear skin. It is a steroid-free cream that targets eczema at a key source.

In a clinical study of patients 2-11, 57% achieved clear or almost clear skin with OPZELURA at 8 weeks compared to 11% using a non-medicated cream.

In a clinical study of patients 12+, 54% achieved clear or almost clear skin with OPZELURA at 8 weeks compared to 15% using a non-medicated cream. Similar results were seen in another clinical study.

The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.

Anna and Rachael standing in front of an All-State Champions sign, lockers, a trophy case, and sports equipment, as they discuss managing eczema with Opzelura.
Anna and Rachael standing in front of an All-State Champions sign, lockers, a trophy case, and sports equipment, as they discuss managing eczema with Opzelura.

Real Stories From real people

Watch the video

Piper & Adam

Triggers like heat and grass caused flare-ups that affected Piper during her favorite outdoor activities. Hear how she and her dad, Adam, navigated finding the right eczema treatment while balancing life as a kid. Results may vary.

Individuals were compensated for their participation.

Watch the video

Anna & Rachael

Anna often experienced eczema flare-ups during the activities she loved. Her mom, Rachael, tried numerous options to help. Hear how their journey led to an eczema treatment that helped Anna find relief while staying active. Results may vary.

Individuals were compensated for their participation.

Watch the video

Dr. Lee

Widely known as Dr. Pimple Popper, Dr. Lee brings unique perspective to her dermatology practice as she not only treats patients, but also treats her own eczema with OPZELURA. Discover her personal experiences with eczema and how that deepened her relationships with her patients. Results may vary.

Individuals were compensated for their participation.

Watch the video

Emily

As Emily grew older and her eczema worsened, her family and coworkers began noticing her flare-ups. See when she realized she needed a change and how she found eczema relief. Results may vary.

Individuals were compensated for their participation.

A real patient smiling and sitting in a workshop setting, sharing his Moments of Clarity with eczema and Opzelura.

DISCOVER MORE MOMENTS

Learn how people living with mild to moderate eczema have experienced their Moments of Clarity, sharing their unique journeys from the challenges of managing their symptoms to finding relief with the help of OPZELURA. Results may vary.

Hear their eczema stories
A real patient smiling and sitting in a workshop setting, sharing his Moments of Clarity with eczema and Opzelura.
A real patient and caregiver smiling, sharing their story managing eczema with Opzelura.
A real patient and caregiver sitting in a living room, sharing their story of managing eczema with Opzelura.
A real patient and caregiver smiling, sharing their story managing eczema with Opzelura.
A real patient and caregiver sitting in a living room, sharing their story of managing eczema with Opzelura.

Talk to a Doctor About Eczema Relief

If you are experiencing challenges getting an in-person appointment with a physician who understands eczema, consider starting the conversation through telehealth. Connect with a provider who has the latest information on eczema and management options from the comfort of your own home.

Connect through telehealth

Incyte does not in any way control or influence any telemedicine healthcare provider. These healthcare providers exercise their own independent medical judgment and are under no obligation to prescribe any medication.

Person holding a tablet during a telehealth appointment.
Person holding a tablet during a telehealth appointment.
 

Indication and Usage

OPZELURA is a prescription medicine used on the skin (topical) for:

  • short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 2 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended
  • the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older

The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.

It is not known if OPZELURA is safe and effective in children less than 2 years of age with atopic dermatitis and less than 12 years with nonsegmental vitiligo.

Important Safety Information

OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death due to any reason (all causes): Increased risk of death has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called JAK inhibitors by mouth.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers have happened in people taking a medicine in the class of medicines called JAK inhibitors by mouth. People taking JAK inhibitors by mouth have a higher risk of certain cancers including lymphoma and lung cancer, especially if they are a current or past smoker. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen.

Increased risk of major cardiovascular events: Increased risk of major cardiovascular events such as heart attack, stroke, or death have happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors by mouth, especially in current or past smokers.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. Blood clots in the vein of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called JAK inhibitors by mouth.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia, lymphopenia, leukopenia). Your healthcare provider may do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.

Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.

Before starting OPZELURA, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have had an infection that does not go away or keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have or have had hepatitis B or C
  • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common
  • think you have an infection or have symptoms of an infection such as: fever, sweating, or chills, muscle aches, cough or shortness of breath, blood in your phlegm, weight loss, warm, red, or painful skin or sores on your body, diarrhea or stomach pain, burning when you urinate or urinating more often than usual, feeling very tired
  • have ever had any type of cancer, or are a current or past smoker
  • have had a heart attack, other heart problems, or a stroke
  • have had blood clots in the veins of your legs or lungs in the past
  • have or have had low white or red blood cell counts
  • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463 or www.opzelura.pregnancy.incyte.com.
  • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose.

After starting OPZELURA:

  • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
  • Get emergency help right away if you have any symptoms of a heart attack, blood clot, or stroke while using OPZELURA, including:
  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded
  • weakness in one part or on one side of your body
  • slurred speech
  • swelling, pain, or tenderness in one or both legs
  • Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath, or fever.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA in people treated for atopic dermatitis include: common cold (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count or decrease in a type of white blood cell (neutropenia) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), runny nose (rhinorrhea), upper respiratory tract infection, COVID-19, fever, and pain, irritation, discomfort, or itching at the application site.

The most common side effects of OPZELURA in people treated for nonsegmental vitiligo include: acne at the application site, itching at the application site, common cold (nasopharyngitis), headache, urinary tract infection, redness at the application site, and fever.

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.